All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-04-06T16:28:31.000Z

AACR 2017 | Poster 2657/16 – PD-L1 blockade enhances T-cell cytotoxicity against Primary Mediastinal B-Cell Lymphoma

Apr 6, 2017
Share:

Bookmark this article

On Monday 3rd April during this year’s American Association for Cancer Research (AACR) annual meeting, a poster (2657 / 16) by Tishi Shah, from New York Medical College, Valhalla, NY, et al. titled “PD-L1 blockade enhances T cell cytotoxicity against Primary Mediastinal B-Cell Lymphoma” was presented.

The group aimed to determine if PD-L1 blockade enhances T-cell responses in PD-L1 positive PMBCL.

Key Highlights:

  • Karpas 1106p cells express a low level of PD-L1
  • After treatment with IFNγ for 48 hrs, PD-L1 expression significantly increased
  • Anti-PD-L1 did not significantly affect T-cell mediated inhibition of cell proliferation in Karpas 1106p cells with low PD-L1 expression
  • Anti-PD-L1 and T-cell treatment significantly inhibited cell proliferation in IFNγ treated Karpas 1106p cells versus treatment with T-cells alone (32±18% vs 3±3% at E:T = 5:1; P = 0.048)

The poster was concluded by stating that T-cell cytotoxicity was heightened by PD-L1 blockade against PMBCL cells. The blockade was dependent on PD-L1 expression, which can be enhanced by administering IFNγ. Future in vivo NSG xenograft studies are ongoing.

  1. Shah T. et al. PD-L1 blockade enhances T cell cytotoxicity against Primary Mediastinal B-Cell Lymphoma [Poster]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; 2017. Poster nr [2657 / 16].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox